Drug news
Shire launches Intuniv (guanfacine extended release) to treat ADHD in the United Kingdom
Shire PLC has now launched Intuniv (guanfacine extended release) in the United Kingdom following an approval on 17 September 2015 to treat ADHD. Intuniv offers ADHD patients, aged six to 17 years, an alternative remedy if they do not respond to or cannot tolerate stimulants. Strattera (atomoxetine) from Eli Lilly is the only other non stimulant therapy for ADHD in Europe, where more than 10% of patients either do not respond to or cannot tolerate treatment with stimulants.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins